Philip G Jones Selected Research

WAY 132983

9/2007

Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip G Jones Research Topics

Disease

40	Myocardial Infarction 01/2020 - 06/2006
17	Heart Failure 12/2021 - 08/2005
7	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 07/2006
7	Acute Coronary Syndrome 10/2017 - 09/2005
7	Diabetes Mellitus 09/2017 - 04/2010
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2005
5	Stroke (Strokes) 01/2021 - 01/2013
5	Heart Arrest (Cardiac Arrest) 01/2017 - 09/2009
4	Coronary Disease (Coronary Heart Disease) 01/2022 - 01/2004
4	Hemorrhage 01/2021 - 01/2013
4	Stable Angina 01/2020 - 05/2013
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 04/2008
4	Hyperglycemia 10/2014 - 02/2008
3	Atrial Fibrillation 01/2021 - 08/2017
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 10/2008
3	Ischemia 01/2020 - 07/2008
3	Hypertension (High Blood Pressure) 12/2019 - 09/2005
3	Unstable Angina 11/2016 - 10/2015
3	Pain (Aches) 09/2007 - 08/2006
2	Schizophrenia (Dementia Praecox) 01/2022 - 10/2019
2	Kidney Diseases (Kidney Disease) 01/2022 - 07/2009
2	Chronic Renal Insufficiency 01/2022 - 01/2020
2	Left Ventricular Dysfunction 12/2019 - 01/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2013 - 09/2005
2	Hypoglycemia (Reactive Hypoglycemia) 07/2012 - 02/2008
2	Ventricular Fibrillation 01/2012 - 09/2009
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 02/2003 - 01/2002
1	Malnutrition (Nutritional Deficiencies) 01/2022
1	Chronic Limb-Threatening Ischemia 01/2022
1	COVID-19 12/2021
1	Embolism (Embolus) 01/2021
1	Disease Progression 12/2020
1	Transient Ischemic Attack 12/2019
1	Peripheral Arterial Disease 12/2019
1	Neurobehavioral Manifestations 10/2019
1	Heart Diseases (Heart Disease) 10/2019
1	Aortic Valve Stenosis (Aortic Stenosis) 01/2019
1	Neoplasms (Cancer) 01/2016
1	Cardiomyopathies (Cardiomyopathy) 01/2016

Drug/Important Bio-Agent (IBA)

7	Glucose (Dextrose)FDA LinkGeneric 09/2015 - 09/2005
4	LipidsIBA 01/2020 - 01/2004
4	Hemoglobins (Hemoglobin)IBA 12/2017 - 10/2014
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 09/2005
3	Angiotensin Receptor AntagonistsIBA 01/2022 - 09/2005
3	Indicators and Reagents (Reagents)IBA 10/2015 - 01/2004
3	Ranolazine FDA Link 11/2014 - 05/2013
3	Nitroglycerin (Dynamite)FDA LinkGeneric 11/2014 - 05/2013
3	Blood Glucose (Blood Sugar)IBA 08/2013 - 03/2009
2	SEP-363856IBA 01/2022 - 10/2019
2	Clopidogrel (Plavix)FDA Link 12/2019 - 01/2013
2	Prasugrel Hydrochloride FDA Link 12/2019 - 01/2013
2	Pharmaceutical PreparationsIBA 05/2018 - 08/2006
2	Mineralocorticoid Receptor AntagonistsIBA 12/2017 - 01/2014
2	Insulin (Novolin)FDA Link 08/2013 - 03/2009
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2012 - 04/2010
2	PPAR alphaIBA 09/2010 - 10/2008
2	Eplerenone (Inspra)FDA LinkGeneric 01/2009 - 04/2007
2	LDL Lipoproteins (beta Lipoproteins)IBA 07/2006 - 01/2004
2	LDL CholesterolIBA 07/2006 - 01/2004
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2002 - 01/2002
1	5-HT1A Serotonin ReceptorIBA 01/2022
1	Trace amine-associated receptor 1IBA 01/2022
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022
1	Dabigatran FDA Link 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	Warfarin (Coumadin)FDA LinkGeneric 01/2021
1	DiureticsIBA 12/2020
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 12/2020
1	TicagrelorIBA 12/2019
1	Chlorpromazine (Thorazine)FDA Link 10/2019
1	Antipsychotic Agents (Antipsychotics)IBA 10/2019
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 10/2019
1	Phencyclidine (Angel Dust)IBA 10/2019
1	OzoneIBA 01/2019
1	Particulate MatterIBA 01/2019
1	AnticoagulantsIBA 05/2018
1	Epoxide HydrolasesIBA 01/2018
1	Amiodarone (Amiodarona)FDA LinkGeneric 08/2017
1	MagnesiumIBA 01/2017
1	omega-Chloroacetophenone (Mace)IBA 01/2017
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2016

Therapy/Procedure

20	Therapeutics 01/2022 - 01/2002
10	Percutaneous Coronary Intervention 01/2020 - 10/2011
8	Patient Readmission 01/2017 - 01/2009
4	Secondary Prevention 01/2020 - 03/2009
4	Stents 12/2016 - 06/2006
3	Resuscitation 01/2017 - 09/2009
3	Drug-Eluting Stents 12/2016 - 06/2006
2	Surgical Amputation (Amputations) 01/2022 - 10/2015
2	Ambulatory Care (Outpatient Care) 12/2021 - 01/2016
2	Transcatheter Aortic Valve Replacement 12/2019 - 01/2019
2	Cardiac Rehabilitation 01/2019 - 12/2016
2	Heart-Assist Devices 01/2016 - 05/2015
2	Transplantation 01/2016 - 05/2015
2	Glycemic Control 10/2014 - 12/2006
1	Conservative Treatment 01/2022
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2020
1	Catheter Ablation 08/2017
1	Catheters 08/2017
1	Dual Anti-Platelet Therapy 12/2016